

**IMS**

Myeloma Cure Summit:

DEFINITIONS, METRICS, AND MILESTONES

FEBRUARY 20-21, 2026 | MIAMI, FL

February 20, 2026

8:00-8:15

INTRODUCTION

Nikhil Munshi, Vincent Rajkumar, Philippe Moreau

8:15-10:00

SESSION 1: DATA FROM LONG TERM FOLLOW UP STUDIES PART I*Chairs: Kenneth Anderson and Jesus San Miguel*

8:15-8:30

IFM

Philippe Moreau

8:30-8:45

Spanish

Laura Rosinol

9:45-9:00

Italian

Mario Boccadoro

9:00-9:15

HOVON

Pieter Sonneveld

9:15-9:30

UK

Gordon Cook

9:30-9:45

Greek

Meletios Dimopoulos

9:45-10:00

German

Marc Raab

10:00-10:15

BREAK

10:15-12:00

SESSION 1: DATA FROM LONG TERM FOLLOW UP STUDIES PART II*Chairs: Kenneth Anderson and Jesus San Miguel*

10:15-10:30

Arkansas

Samer Al Hadidi

10:30-10:45

Mayo

Vincent Rajkumar

10:45-11:00

ECOG SWOG

Shaji Kumar

11:00-11:15

Industry Studies With Long Follow-up

Paul Richardson

11:15-12:00

Discussion

Nizar Bahlis, Faith Davies,
Joy Ho, Evangelos Terpos

12:00-1:00

LUNCH

1:00-3:00

SESSION 2: WHAT SHOULD BE CALLED A CURE - DEFINITION*Chairs: Nikhil Munshi and Philippe Moreau*

1:00-1:10

MRD Depth

Nikhil Munshi

1:10-1:20

Cure Fraction Models: What Does the Estimated Cure
Fraction Really Mean?

John Crowley

1:20-1:30

Imaging

Elena Zamagni

1:30-1:40

Sustained With or Without Treatment

Noopur Raje

1:40-1:50

Immune Reconstitution

Madhav Dhodapkar

1:50-2:00

Off-Therapy Duration

Sundar Jagannath

2:00-2:10

QOL - Return to Work Concept

Sonja Zweegman

2:10-2:20

Attaining MGUS State

Maria-Victoria Mateos

2:20-3:00

Discussion

3:00-3:30

BREAK

3:30-5:00

SESSION 3: PATIENT SUB-GROUP CONSIDERATIONS - WHO MAY BE CURABLE

Chairs: Vincent Rajkumar and Suzanne Lentzsch

3:30-3:40	Age Groups: Are Young More Likely to be Cured?	Charlotte Pawlyn
3:40-3:50	Disease Risk Considerations: HR vs SR Which One is More Curable?	Katja Weisel
3:50-4:00	Administration of the Types of Therapy: Do We Need Cytotoxic Agents for Cure?	Saad Usmani
4:00-4:10	Genomic Correlates of Cure?	Mehmet Samur
4:10-5:00	Discussion	Niccolo Bolli, Robert Orlowski, Surbhi Sidana, Raphael Szalat

5:00-6:00

SESSION 4: PATIENT VOICES

Chair: Vania Hungria and Ravi Vij

5:00-5:15	What Does it Mean for Them?	TBD
5:15-5:30	A Patient Who May be Considered Cured	TBD
5:30-6:00	Discussion	Adam Cohen, Francesca Gay, Ola Landgren, Paola Neri

February 21, 2026

8:30-10:45

SESSION 5: REVIEW OF CURATIVE MALIGNANCIES - HOW DID THEY ACHIEVE CURE? WHAT IS THEIR DEFINITION

Chairs: TBD

8:30-8:40	Testicular Cancer	TBD
8:40-8:50	Acute Myeloid Leukemia	TBD
8:50-9:00	Pediatric Leukemia	TBD
9:00-9:10	Hodgkin's Disease	TBD
9:10-9:20	High-grade Lymphoma	TBD
9:20-9:30	Chronic Myeloid Leukemia	TBD
9:30-9:40	Therapy De-escalation in Curative Cancer	TBD
9:40-9:50	Off Therapy: Time to Define Cure	TBD
9:50-10:00	What Does Late Relapse Mean in Defining Cure?	TBD
10:00-10:45	Discussion	Gareth Morgan, Adam Sperling

10:45-11:15

BREAK

11:15-1:15

SESSION 6: WHAT THERAPIES MAY LEAD TO A CURE: STUDIES AND THERAPIES ARE POTENTIALLY ABLE TO INCREASE CURE FRACTIONS

Chairs: Shaji Kumar and Maria-Victoria Mateos

11:15-11:30	Cure Concept 1	Sagar Lonial
11:30-11:45	Cure Concept 2	Hermann Einsele
11:45-12:00	Cure Concept 3	Ajai Chari
12:00-12:15	Cure Concept 4	Niels van de Donk
12:15-12:30	Cure Concept 5 - Early Intervention	Irene Ghobrial
12:30-1:15	Discussion	Xavier Leleu, Ajay Nooka, Fredrik Schjesvold

1:15-2:30

LUNCH

2:30-3:30

SESSION 7: CONSENSUS CONSIDERATION AND FUTURE STUDIES TO FURTHER REFINE CURE

Kenneth Anderson, Shaji Kumar, Nikhil Munshi, Philippe Moreau, Vincent Rajkumar, Jesus San Miguel

The International Myeloma Society gratefully acknowledges the following organizations for their support of the summit:



Johnson & Johnson

